Join Growin Stock Community!

Unicycive therapeutics, inc.UNCY.US Overview

US StockHealthcare
(No presentation for UNCY)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

UNCY AI Insights

UNCY Overall Performance

UNCY AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

UNCY Recent Performance

-1.15%

Unicycive therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

UNCY PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

UNCY Key Information

UNCY Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

UNCY Profile

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Price of UNCY

UNCY FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

UNCY Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.56
PE Ratio (TTM)
-
Forward PE
4.14
PS Ratio (TTM)
23.75
PB Ratio
3.98
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.56
PE Ratio (TTM)
-
Forward PE
4.14
PS Ratio (TTM)
23.75
PB Ratio
3.98
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is UNCY's latest earnings report released?

    The most recent financial report for Unicycive therapeutics, inc. (UNCY) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating UNCY's short-term business performance and financial health. For the latest updates on UNCY's earnings releases, visit this page regularly.

  • How much cash does UNCY have?

    At the end of the period, Unicycive therapeutics, inc. (UNCY) held Total Cash and Cash Equivalents of 42.7M, accounting for 0.84 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is UNCY's EPS continuing to grow?

    According to the past four quarterly reports, Unicycive therapeutics, inc. (UNCY)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.33. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of UNCY?

    Unicycive therapeutics, inc. (UNCY)'s Free Cash Flow (FCF) for the period is -5.96M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 35.71% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of UNCY?

    The latest valuation data shows Unicycive therapeutics, inc. (UNCY) has a Price-To-Earnings (PE) ratio of -3.3 and a Price/Earnings-To-Growth (PEG) ratio of 0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.